{
  "trade_id": "TRD-20260119-RGNX-PDUFA",
  "ticker": "RGNX",
  "archetype": "pdufa",
  "status": "active",
  "instrument_type": "equity",

  "thesis": {
    "summary": "RGX-121 gene therapy for Hunter Syndrome (MPS II) with PDUFA Feb 8, 2026. FDA inspections passed with no objections. Review extended for positive 12-month data. First gene therapy for this indication. Multiple favorable designations (Orphan, Rare Pediatric Disease, Fast Track, RMAT).",
    "catalyst": "FDA PDUFA decision on RGX-121",
    "catalyst_date": "2026-02-08",
    "linked_event": "EVT-2026-038"
  },

  "scoring": {
    "catalyst": 2.0,
    "mispricing": 2.0,
    "noise_survival": 1.5,
    "downside_floor": 1.0,
    "risk_reward": 2.0,
    "info_half_life": 0.5,
    "base_score": 9.0,
    "adjustments": [],
    "final_score": 9.0,
    "kill_screen_notes": "D/E 1.66 exceeds 0.75 threshold but net cash position is positive (~$198M). Conditional pass granted due to accounting distortion from convertible notes/leases."
  },

  "decision": {
    "action": "BUY",
    "date": "2026-01-19",
    "rationale": "Score 9.0 exceeds threshold 8.25. Clean FDA inspection record, positive clinical data, multiple regulatory designations support high approval probability. 105% upside to analyst target."
  },

  "position": {
    "entry_date": "2026-01-19",
    "entry_price": 13.62,
    "shares": 27,
    "cost_basis": 367.74,
    "size_percent": 0.0147,
    "stop_price": 8.00,
    "target_price": 30.78
  },

  "exit_plan": {
    "info_parity_weights": {
      "media": 0.5,
      "iv": 1.5,
      "price": 1.0
    },
    "thesis_break_triggers": [
      "FDA issues Complete Response Letter (CRL)",
      "FDA requests additional clinical data or trials",
      "Safety signal emerges",
      "Manufacturing issues at CMO"
    ],
    "pdufa_specific": {
      "approval": "Evaluate sell-the-news vs hold for commercial ramp",
      "crl": "Exit immediately at market",
      "delay": "Re-evaluate based on reason for delay"
    }
  },

  "monitoring": [
    {
      "date": "2026-01-19",
      "price": 13.62,
      "change_from_entry_pct": 0.0,
      "unrealized_pnl": 0.0,
      "info_parity": {
        "media": 0,
        "iv": 0,
        "price": 0
      },
      "weighted_sum": 0.0,
      "ma_200": 10.17,
      "above_200_ma": true,
      "cockroaches": [],
      "thesis_breaks": [],
      "action": "OPEN",
      "notes": "Position opened. 20 days to PDUFA. Price above 200-MA (bullish). FDA inspections passed. Positive 12-month data submitted. Strong regulatory pathway."
    },
    {
      "date": "2026-01-20",
      "price": 14.13,
      "change_from_entry_pct": 0.0374,
      "unrealized_pnl": 13.77,
      "info_parity": {
        "media": 0,
        "iv": 0,
        "price": 0.030
      },
      "weighted_sum": 0.030,
      "ma_200": 10.21,
      "above_200_ma": true,
      "cockroaches": [],
      "thesis_breaks": [],
      "action": "HOLD",
      "notes": "Price $14.13 (+3.7% from entry), strong start. Above 200-day MA ($14.13 > $10.21) = strong technical positioning. PDUFA Feb 8, 2026 (19 days away). FDA completed pre-license and bioresearch inspections with NO observations. Review extension was to incorporate positive 12-month CAMPSIITE trial data. Pivotal trial (n=13) showed 82% median reduction in CSF heparan sulfate. Multiple favorable designations (Orphan, RMAT, Fast Track). Nippon Shinyaku partnership for US/Asia commercialization. No mainstream media coverage yet (info parity NOT triggered). Weighted sum 0.030 < 2.0 threshold. Thesis intact. Data sources: Stooq (price), Yahoo Finance (200-MA), web search (media)."
    },
    {
      "date": "2026-01-21",
      "price": 14.94,
      "change_from_entry_pct": 0.0969,
      "unrealized_pnl": 35.64,
      "info_parity": {
        "media": 0,
        "iv": 0,
        "price": 0.077
      },
      "weighted_sum": 0.077,
      "ma_200": 10.25,
      "above_200_ma": true,
      "cockroaches": [],
      "thesis_breaks": [],
      "action": "HOLD",
      "notes": "Price $14.94 (+9.7% from entry), very strong performance. Above 200-day MA ($14.94 > $10.25) = strong technical positioning. PDUFA Feb 8, 2026 (18 days away). FDA completed pre-license and bioresearch monitoring inspections with NO observations - strong approval signal. Review extension was to incorporate positive 12-month CAMPSIITE pivotal data (n=13, 82% median CSF heparan sulfate reduction). Multiple favorable designations: Orphan Drug, Rare Pediatric Disease, Fast Track, RMAT. Nippon Shinyaku partnership for US/Asia commercialization. Potential Priority Review Voucher (PRV) on approval. No mainstream media coverage (info parity NOT triggered). Weighted sum 0.08 < 2.0 threshold. Thesis strongly intact. Data sources: Stooq (price), Yahoo Finance (200-MA), web search (media)."
    },
    {
      "date": "2026-01-23",
      "price": 14.00,
      "change_from_entry_pct": 0.0279,
      "unrealized_pnl": 10.26,
      "info_parity": {
        "media": 0,
        "iv": 0,
        "price": 0.022
      },
      "weighted_sum": 0.022,
      "ma_200": 10.34,
      "above_200_ma": true,
      "cockroaches": [],
      "thesis_breaks": [],
      "action": "HOLD",
      "notes": "Price $14.00 (+2.8% from entry), still above 200-day MA ($14.00 > $10.34). PDUFA Feb 8, 2026 (16 days away). Media signal not checked (manual search required). IV data unavailable. 2.2% progress to target (below 50% threshold). Thesis intact. Data sources: Stooq (price), Yahoo Finance (200-MA)."
    }
  ],

  "key_dates": {
    "pdufa_date": "2026-02-08",
    "days_to_catalyst": 18,
    "next_earnings": "2026-03-03",
    "entry_90_day_review": "2026-04-19"
  }
}
